Analysts Expect Theravance Biopharma Inc (NASDAQ:TBPH) Will Announce Quarterly Sales of $17.58 Million

Share on StockTwits

Equities analysts expect Theravance Biopharma Inc (NASDAQ:TBPH) to announce sales of $17.58 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Theravance Biopharma’s earnings. The lowest sales estimate is $11.50 million and the highest is $32.30 million. Theravance Biopharma posted sales of $15.74 million in the same quarter last year, which would indicate a positive year over year growth rate of 11.7%. The company is expected to issue its next quarterly earnings report on Tuesday, February 25th.

On average, analysts expect that Theravance Biopharma will report full-year sales of $61.26 million for the current financial year, with estimates ranging from $55.00 million to $76.20 million. For the next year, analysts expect that the company will post sales of $94.22 million, with estimates ranging from $74.18 million to $129.80 million. Zacks’ sales averages are an average based on a survey of research firms that cover Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, meeting the consensus estimate of ($1.05). The firm had revenue of $12.43 million during the quarter, compared to analysts’ expectations of $13.33 million.

Several analysts recently commented on the stock. Robert W. Baird upgraded shares of Theravance Biopharma from an “underperform” rating to a “neutral” rating and reduced their price objective for the company from $22.00 to $18.00 in a research note on Wednesday, November 6th. HC Wainwright started coverage on shares of Theravance Biopharma in a research note on Tuesday, October 29th. They set a “buy” rating and a $25.00 price objective for the company. Piper Jaffray Companies cut their price target on shares of Theravance Biopharma from $55.00 to $40.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. BidaskClub upgraded shares of Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $33.40.

Shares of NASDAQ TBPH traded up $1.93 during mid-day trading on Wednesday, reaching $21.15. The company had a trading volume of 435,258 shares, compared to its average volume of 251,217. Theravance Biopharma has a 52-week low of $15.18 and a 52-week high of $29.45. The stock has a market cap of $1.03 billion, a P/E ratio of -5.30 and a beta of 1.66. The firm has a 50 day simple moving average of $17.36 and a two-hundred day simple moving average of $18.77.

A number of institutional investors have recently bought and sold shares of TBPH. Vanguard Group Inc. increased its holdings in Theravance Biopharma by 1.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,932,787 shares of the biopharmaceutical company’s stock valued at $64,223,000 after purchasing an additional 54,562 shares during the period. BlackRock Inc. grew its position in shares of Theravance Biopharma by 3.1% during the second quarter. BlackRock Inc. now owns 3,832,682 shares of the biopharmaceutical company’s stock valued at $62,587,000 after purchasing an additional 116,009 shares in the last quarter. State Street Corp lifted its holdings in shares of Theravance Biopharma by 1.0% in the 3rd quarter. State Street Corp now owns 947,616 shares of the biopharmaceutical company’s stock valued at $18,460,000 after acquiring an additional 9,112 shares during the last quarter. Northern Trust Corp raised its stake in shares of Theravance Biopharma by 0.6% during the second quarter. Northern Trust Corp now owns 553,629 shares of the biopharmaceutical company’s stock valued at $9,041,000 after acquiring an additional 3,547 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in Theravance Biopharma by 15.3% during the second quarter. Jacobs Levy Equity Management Inc. now owns 309,873 shares of the biopharmaceutical company’s stock valued at $5,060,000 after buying an additional 41,060 shares during the period. Institutional investors and hedge funds own 79.64% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Featured Story: How is a price target determined?

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.